Search

Your search keyword '"Sese, E"' showing total 13 results
Start Over Author "Sese, E"
13 results on '"Sese, E"'

1. Comparative study of the effectiveness of vedolizumab versus ustekinumab after anti-TNF failure (VERSUS-CD)

Author

Garcia, MJ, Rivero, M, Fernandez-Clotet, A, de Francisco, R, Sicilia, B, Mesonero, F, de Castro, ML, Casanova, MJ, Bertoletti, F, Alonso, FJG, Garcia, AL, Julian, B, Calvet, X, Acosta, MBD, Jara, L, Varela, P, Nunez, A, Ricart, E, Riestra, S, Arias, L, Rodriguez, M, Arranz, L, Pajares, R, Mena, R, Calafat, M, Camo, P, Jimenez, L, Ponferrada, A, Madrigal, RE, Llao, J, Sese, E, Almela, P, Codesido, L, de la Maza, S, Leal, C, Sanchez, E, Marino, JRP, Domenech, E, Chaparro, M, and Gisbert, JP

Published
2022

2. Low adhesion to latent tuberculosis (TB) screening recommendations in inflammatory bowel disease (IBD) patients: Results of the INFEII registry of GETECCU

Author

Abdo, YZ, de Francisco, R, Rodriguez-Lago, I, Chaparro, M, Gomollon, F, Piqueras, M, Llao, J, Sicilia, B, Domenech, E, Garcia-Bosch, O, de Castro, L, Calvet, X, Morales, V, Rivero, M, Lucendo, AJ, Navarro, P, Marquez, L, Busquets, D, Guardiola, J, Gordillo, J, Iglesias, E, Beltran, B, Sese, E, Ferreiro-Iglesias, R, Francisco, M, Pajares, R, Algaba, A, Vicente, R, Benitez, O, Aceituno, M, Riestra, S, Rodriguez-Pescador, A, Gisbert, JP, Arroyo, MT, Mena, R, Sainz, E, Arias-Garcia, L, Manosa, M, Navarro, M, Sanroman, L, Villoria, A, Delgado-Villena, P, Garcia, MJ, Angueira, T, Minguez, M, Murciano, F, Arajol, C, and Esteve, M

Published
2020

3. Comparison of the efficacy of a second intravenous or subcutaneous anti-TNF in the treatment of ulcerative colitis: Real-world data from the ENEIDA registry

Author

Torres-Rodriguez, P, Canete, F, Calafat, M, Sanchez-Aldehuelo, R, Rivero, M, Iborra, M, Gonzalez-Vivo, M, Vera, I, de Castro, L, Bujanda, L, Barreiro-de Acosta, M, Calvet, X, Benitez, J, Llorente, M, Suris, G, Arias-Garcia, L, David, M, Castano-Garcia, A, Garcia-Alonso, F, Rufo, L, Ferrer, J, Camo, P, Gisbert, J, Huguet, J, Pajares, R, Morales, V, Llao, J, Rodriguez, A, Rodriguez, C, Navarro, M, Gomollon, F, Carrillo-Palau, M, Sese, E, Almela, P, de la Piscina, P, Rodriguez-Lago, I, Papo, M, Vela, M, Manosa, M, Domenech, E, and Eneida-GETECCU Investigators

Published
2020

4. Differences between childhood- and adulthood-onset inflammatory bowel disease: the CAROUSEL study from GETECCU

Author

Chaparro, M, Garre, A, Ricart, E, Iglesias-Flores, E, Taxonera, C, Manosa, M, Mendoza, IV, Minguez, M, Arguelles, F, Parga, LD, Arroyo, M, Lopez-Sanroman, A, Tirado, MR, Guardiola, J, Arranz, MDM, Beltran, B, Barrio, J, Riestra, S, Garcia-Planella, E, Calvet, X, Alcain, G, Sicilia, B, Garcia, S, Esteve, M, Marquez, L, Salazar, LIF, Casbas, AG, Piqueras, M, Bermejo, F, Calle, JLP, Hinojosa, J, Perez, AR, Aldeguer, X, Sepulcre, MFG, Bujanda, L, Montiel, PM, Poyatos, RL, Gutierrez, CR, Merino, O, Cabriada, JL, Roncero, O, Cara, PR, Navarro-Llavat, M, Ber, Y, Madrigal, RE, Van Domselaar, M, Barreiro-de Acosta, M, Llao, J, Ramos, L, Riera, J, Villarin, AJL, Gonzalez, ER, Malaves, JMH, Villafranca, CM, Almela, P, Charro, M, de la Piscina, PR, Sese, E, Lacruz, AA, Khorrami, S, Alvarado, VJM, Gil, JL, Martinez, AMT, Villaroya, RP, Acevedo, J, Herola, AG, Villalba, LH, Munoz, E, Duran, MTN, Menacho, M, Lopez, VMN, Retamero, MD, Bernardo, D, Muriel, A, Domenech, E, Gisbert, JP, and ENEIDA Study Grp

Abstract

Background Cohort studies comparing the characteristics of childhood-onset and adulthood-onset inflammatory bowel disease (IBD) in the biologics era are scarce. Aim To compare disease characteristics, the use of immunomodulators and biologic agents and the need for surgery between childhood- and adulthood-onset IBD. Methods Inflammatory bowel disease patients from the ENEIDA registry diagnosed between 2007 and 2017 were included. The childhood-onset cohort comprised patients diagnosed at 16 years. The cumulative incidences of immunosuppressive therapy, biologic therapy and surgery were estimated using Kaplan-Meier curves, compared by the log-rank test. Cox regression analysis was performed to identify potential predictive factors of treatment with immunosuppressants, biologic agents or surgery. Results The adulthood-onset cohort comprised 21 200 patients out of 20 354 (96%) and the childhood-onset cohort 846 (4%). Median follow-up was 54 months in the childhood-onset cohort and 38 months in the adulthood-onset cohort (P < 0.01). Proportions of Crohn's disease, ileocolonic involvement and inflammatory behaviour at diagnosis were higher in the childhood-onset cohort. In the multivariate analysis, after adjusting for sex, type of IBD, extraintestinal manifestations, family history and smoking habit, childhood-onset IBD was associated with higher risk of immunomodulator use (hazard ratio [HR] = 1.2, 95% confidence interval [95% CI] = 1.1-1.2) and higher probability of receiving biologic treatment (HR = 1.2, 95% CI = 1.1-1.3). However, childhood-onset IBD was not associated with higher risk of surgery (HR = 0.9, 95% CI = 0.8-1.2). Conclusions Childhood-onset IBD has differential characteristics and higher risk of treatment with immunomodulators and biologic agents, compared with adulthood-onset IBD. Nevertheless, paediatric IBD is not associated with higher risk of surgery.

Published
2019

5. Increased risk of thiopurine-related adverse events in elderly patients with IBD

Author

Calafat M, Manosa M, Canete F, Ricart E, Iglesias E, Calvo M, Rodriguez-Moranta F, Taxonera C, Nos P, Mesonero F, Martin-Arranz M, Minguez M, Gisbert J, Garcia-Lopez S, de Francisco R, Gomollon F, Calvet X, Garcia-Planella E, Rivero M, Martinez-Cadilla J, Arguelles F, Arias L, Cimavilla M, Zabana Y, Domenech E, Abad A, Alcain G, Almela P, Barreiro-de-Acosta M, Ber Y, Bermejo F, Bujanda L, Busquets D, Charro M, Garcia-Bosch O, Garcia-Sepulcre M, Gutierrez A, Khorrami S, Lazaro J, Legido J, Liao J, Lucendo A, Madrigal R, Marquez L, Martinez-Montiel P, Merino O, Monfort D, Mora M, Munoz-Villafranca C, Ramos L, Riera J, Perez A, Gutierrez C, Rodriguez-Pescador A, Romero P, Roncero O, Sese E, Trapero A, Van Domselaar M, Vela M, Velayos B, Verdejo C, Huguet J, and ENEIDA Registry GETECCU

Abstract

Background Thiopurines are the most widely used immunosuppressants in IBD although drug-related adverse events (AE) occur in 20%-30% of cases. Aim To evaluate the safety of thiopurines in elderly IBD patients Methods Cohort study including all adult patients in the ENEIDA registry who received thiopurines. Patients were grouped in terms of age at the beginning of thiopurine treatment, specifically in those who started thiopurines over 60 years or between 18 and 50 years of age. Thiopurine-related AEs registered in the ENEIDA database were compared. Results Out of 48 752 patients, 1888 thiopurines when over 60 years of age and 15 477 under 50 years of age. Median treatment duration was significantly shorter for those who started thiopurines >60 years (13 [IQR 2-55] vs 32 [IQR 5-82] months; P < .001). Patients starting >60 years had higher rates of all types of myelotoxicity, digestive intolerance and hepatotoxicity. Thiopurines were discontinued due to AEs (excluding malignancies and infections) in more patients starting >60 years (67.2% vs 63.1%; P < .001). Elderly age and female sex were independent risk factors for most AEs. Conclusion In elderly IBD patients, thiopurines are associated with an increased risk of non-infectious, non-neoplastic, AEs.

Published
2019

6. Risk of immunomediated adverse events or secondary loss of response to infliximab in elderly patients with inflammatory bowel disease: a cohort study of the ENEIDA registry

Author

Calafat, M, Manosa, M, Panes, J, Nos, P, Iglesias, E, Vera, I, Lopez-Sanroman, A, Guardiola, J, Taxonera, C, Minguez, M, Martin, MD, de Castro, L, Riestra, S, Rivero, M, Garcia-Planella, E, Calvet, X, Garcia-Lopez, S, Andreu, M, Gomollon, F, Barrio, J, Esteve, M, Rodriguez, A, Gisbert, JP, Gutierrez, A, Hinojosa, J, Arguelles, F, Busquets, D, Bujanda, L, Lazaro, J, Sicilia, B, Merino, O, Martinez, P, Bermejo, F, Lorente, R, Barreiro-de-Acosta, M, Rodriguez, C, Fe, M, Piqueras, M, Romero, P, Rodriguez, E, Roncero, O, Llao, J, Alcain, G, Riera, J, Sierra, M, Salazar, LIF, Jair, V, Navarro, M, Montoro, MA, Munoz, C, Lucendo, AJ, Van Domselaar, M, Moraleja, I, Huguet, M, Ramos, L, Ramirez, P, Almeda, P, Pajares, R, Khorrami, S, Madrigal, RE, Sese, E, Trapero, AM, Legido, J, Abad, A, Canete, F, Cabre, E, and Domenech, E

Published
2019

7. P156 Differential characteristics of patients with inflammatory bowel disease onset in paediatric age compared with patients diagnosed in adulthood: Results from the CAROUSEL study of GETECCU

Author

Chaparro, M, primary, Garre, A, additional, Ricart, E, additional, García-Sánchez, V, additional, Taxonera, C, additional, Mañosa, M, additional, Vera Mendoza, I, additional, Mínguez, M, additional, Argüelles, F, additional, De Castro Parga, L, additional, Arroyo, M, additional, López-San Román, A, additional, Rivero Tirado, M, additional, Guardiola, J, additional, Martín Arranz, M D, additional, Beltrán, B, additional, Barrio, J, additional, Riestra, S, additional, García-Planella, E, additional, Calvet, X, additional, Alcaín, G, additional, Sicilia, B, additional, García, S, additional, Esteve, M, additional, Márquez, L, additional, Fernández Salazar, L, additional, Gutiérrez Casbas, A, additional, Piqueras, M, additional, Guerra, I, additional, Pérez Calle, J L, additional, Hinojosa, J, additional, Rodríguez, A, additional, Aldeguer, X, additional, García-Sepulcre, M, additional, Bujanda, L, additional, Martínez Montiel, P, additional, Llorente Poyatos, R, additional, Rodríguez Gutiérrez, C, additional, Merino, O, additional, Cabriada, J L, additional, Roncero, O, additional, Romero Cara, P, additional, Navarro-Llavat, M, additional, Ber, Y, additional, Madrigal, R, additional, Van Domselaar, M, additional, Barreiro-de Acosta, M, additional, Llao, J, additional, Ramos, L, additional, Riera, J, additional, Lucendo Villarín, A J, additional, Rodríguez González, E, additional, Huguet Malavés, J M, additional, Muñoz Villafranca, C, additional, Almela, P, additional, Charro, M, additional, Ramírez de la Piscina, P, additional, Sese, E, additional, Abad Lacruz, Á, additional, Khorrami, S, additional, Morales Alvarado, V J, additional, Legido Gil, J, additional, Trapero Martínez, A M, additional, Pajares, R, additional, Acevedo, J, additional, García Herola, A, additional, Hernández Villalba, L, additional, Muñoz, E, additional, Novella Durán, M T, additional, Menacho, M, additional, Navas López, V M, additional, Retamero, M D, additional, Domènech, E, additional, and Gisbert, J P, additional

Published
2018
Full Text
View/download PDF

8. The availability of anti-TNF agents is associated with reduced early surgical requirements in Crohn's disease but not in ulcerative colitis. A nationwide study from the Eneida registry

Author

Guasch, M., Clos, A., Ordas, I., Garcia-Sanchez, V., Gisbert, J. P., Taxonera, C., Vera, I., Minguez, M., Guardiola, J., Lopez-Sanroman, A., Rivero-Tirado, M., Nos, P., Gomollon, F., Carbajo, A. Y., Francisco, R., Martin-Arranz, M. D., Garcia-Planella, E., Garcia-Lopez, S., Castro, L., Calvet, X., Camargo, R., Esteve, M., Sicilia, B., Andreu, M., Macho, A., Piqueras, M., Bermejo, F., Gutierrez, A., Busquets, D., Martinez-Montiel, P., Hinojosa, J., Perez-Calle, J. L., Luis Bujanda, Rodriguez-Perez, A., Lorente, R., Jimenez, N., Navarro-Llavat, M., Cabriada, J. L., Camo, P., Domselaar, M., Rodriguez-Gonzalez, E., Rodriguez-Gutierrez, C., Huguet, J. M., Lucendo, A. J., Arguelles, F., Almela, P., Merino, O., Calafat, M., Ogueta, M., Charro, M., Llao, J., Munoz, C., Ramos, L., Abad, A., Roncero, O., Barreiro-De-Acosta, M., Sese, E., Manosa, M., and Domenech, E.

9. The initiation of thiopurines in elderly patients with inflammatory bowel disease is associated with an increased risk of adverse effects: a case-control study of the ENEIDA registry

Author

Calafat, M., Manosa, M., Canete, F., Panes, J., Garcia Sanchez, V., Calvo, M., Rodriguez-Moranta, F., Taxonera, C., Nos, P., Lopez Sanroman, A., Martin Arranz, M. D., Minguez, M., Gisbert, J. P., Garcia-Lopez, S., Francisco, R., Gomollon, F., Calvet, X., Garcia-Planella, E., Rivero, M., Martinez-Cadilla, J., Arguelles, F., Arias Garcia, L., Cimavilla, M., Zabana, Y., Marquez, L., Gutierrez, A., Alcain, G., Martinez Montiel, P., Lazaro, J., Busquets, D., Garcia Sepulcre, M. F., Verdejo, C., Bermejo, F., Mora, M., Monfort, D., Romero, P., Velayos, B., Rodriguez, C., Rodriguez, A., Merino, O., Rodriguez-Pescador, A., Luis Bujanda, Ber, Y., Vela, M., Roncero, O., Huguet, J. M., Garcia-Bosch, O., Barreiro-De-Acosta, M., Madrigal, R. E., Ramos, L., Domselaar, M., Almela, P., Llao, J., Lucendo, A. J., Munoz Vilafranca, C., Abad, A., Charro, M., Legido, J., Riera, J., Khorrami, S., Sese, E., Trapero, A. M., and Domenech, E.

10. Differential characteristics of patients with inflammatory bowel disease onset in paediatric age compared with patients diagnosed in adulthood: Results from the CAROUSEL study of GETECCU

Author

Chaparro, M., Garre, A., Ricart, E., Garcia-Sanchez, V., Taxonera, C., Manosa, M., Vera Mendoza, I., Minguez, M., Arguelles, F., Castro Parga, L., Arroyo, M., Lopez-San Roman, A., Rivero Tirado, M., Guardiola, J., Martin Arranz, M. D., Beltran, B., Barrio, J., Riestra, S., Garcia-Planella, E., Calvet, X., Alcain, G., Sicilia, B., Garcia, S., Esteve, M., Marquez, L., Fernandez Salazar, L., Gutierrez Casbas, A., Piqueras, M., Guerra, I., Perez Calle, J. L., Hinojosa, J., Rodriguez, A., Aldeguer, X., Garcia-Sepulcre, M., Bujanda, L., Martinez Montiel, P., Llorente Poyatos, R., Rodriguez Gutierrez, C., Merino, O., Cabriada, J. L., Octavio Roncero, Romero Cara, P., Navarro-Llavat, M., Ber, Y., Madrigal, R., Domselaar, M., Barreiro-De Acosta, M., Llao, J., Ramos, L., Riera, J., Lucendo Villarin, A. J., Rodriguez Gonzalez, E., Huguet Malaves, J. M., Munoz Villafranca, C., Almela, P., Charro, M., Ramirez La Piscina, P., Sese, E., Abad Lacruz, A., Khorrami, S., Morales Alvarado, V. J., Legido Gil, J., Trapero Martinez, A. M., Pajares, R., Acevedo, J., Garcia Herola, A., Hernandez Villalba, L., Munoz, E., Novella Duran, M. T., Menacho, M., Navas Lopez, V. M., Retamero, M. D., Domenech, E., and Gisbert, J. P.

11. Comparison of the efficacy of a second intravenous or subcutaneous anti-TNF in the treatment of ulcerative colitis: Real-world data from the ENEIDA registry

Author

Torres-Rodriguez, P., Canete, F., Calafat, M., Sanchez-Aldehuelo, R., Rivero, M., Iborra, M., Gonzalez-Vivo, M., Vera, I., Castro, L., Luis Bujanda, Barreiro-De Acosta, M., Calvet, X., Benitez, J. M., Llorente, M., Suris, G., Arias-Garcia, L., David, M., Castano-Garcia, A., Garcia-Alonso, F. J., Rufo, L., Ferrer, J. A., Camo, P., Gisbert, J. P., Huguet, J. M., Pajares, R., Morales, V., Llao, J., Rodriguez, A., Rodriguez, C., Navarro, M., Gomollon, F., Carrillo-Palau, M., Sese, E., Almela, P., Ramirez La Piscina, P., Rodriguez-Lago, I., Papo, M., Vela, M., Manosa, M., and Domenech, E.

12. Endoscopic treatment (endoscopic balloon dilation/self-expandable metal stent) vs surgical resection for the treatment of de novo stenosis in Crohn's disease (ENDOCIR study): an open-label, multicentre, randomized trial.

Author

Loras C, Ruiz-Ramirez P, Romero J, Andújar X, Bargallo J, Bernardos E, Boscá-Watts MM, Brugiotti C, Brunet E, Busquets D, Cerrillo E, Cortina FJ, Díaz-Milanés JA, Dueñas C, Farrés R, Golda T, González-Huix F, Gornals JB, Guardiola J, Julià D, Lira A, Llaó J, Mañosa M, Marin I, Millán M, Monfort D, Moro D, Mullerat J, Navarro M, Pérez Roldán F, Pijoan E, Pons V, Reyes J, Rufas M, Sainz E, Sanchiz V, Serracant A, Sese E, Soto C, Troya J, Zaragoza N, Tebé C, Paraira M, Sudrià-Lopez E, Mayor V, Fernández-Bañares F, and Esteve M

Subjects
Humans, Constriction, Pathologic, Dilatation, Quality of Life, Treatment Outcome, Stents adverse effects, Crohn Disease complications, Crohn Disease diagnosis, Crohn Disease surgery
Abstract

Background: Stenosis is one of the most common complications in patients with Crohn's disease (CD). Endoscopic balloon dilation (EBD) is the treatment of choice for a short stenosis adjacent to the anastomosis from previous surgery. Self-expandable metal stents (SEMS) may be a suitable treatment option for longer stenoses. To date, however, there is no scientific evidence as to whether endoscopic (EBD/SEMS) or surgical treatment is the best approach for de novo or primary stenoses that are less than 10 cm in length., Methods/design: Exploratory study as "proof-of-concept", multicentre, open-label, randomized trial of the treatment of de novo stenosis in the CD; endoscopic treatment (EBD/SEMS) vs surgical resection (SR). The type of endoscopic treatment will initially be with EDB; if a therapeutic failure occurs, then a SEMS will be placed. We estimate 2 years of recruitment and 1 year of follow-up for the assessment of quality of life, costs, complications, and clinical recurrence. After the end of the study, patients will be followed up for 3 years to re-evaluate the variables over the long term. Forty patients with de novo stenosis in CD will be recruited from 15 hospitals in Spain and will be randomly assigned to the endoscopic or surgical treatment groups. The primary aim will be the evaluation of the patient quality of life at 1 year follow-up (% of patients with an increase of 30 points in the 32-item Inflammatory Bowel Disease Questionnaire (IBDQ-32). The secondary aim will be evaluation of the clinical recurrence rate, complications, and costs of both treatments at 1-year follow-up., Discussion: The ENDOCIR trial has been designed to determine whether an endoscopic or surgical approach is therapeutically superior in the treatment of de novo stenosis in CD., Trial Registration: ClinicalTrials.gov NCT04330846. Registered on 1 April 1 2020. https://clinicaltrials.gov/ct2/home., (© 2023. The Author(s).)

Published
2023
Full Text
View/download PDF

13. Low complement levels and opsonic activity in hepatic hydrothorax: its relationship with spontaneous bacterial empyema.

Author

Sese E, Xiol X, Castellote J, Rodríguez-Fariñas E, and Tremosa G

Subjects
Ascites physiopathology, Empyema, Pleural physiopathology, Humans, Hydrothorax physiopathology, Liver Cirrhosis physiopathology, Pleural Effusion physiopathology, Prospective Studies, Complement C3 analysis, Liver Cirrhosis complications, Opsonin Proteins analysis, Pleural Effusion chemistry
Abstract

Goals: To analyze the pleural fluid factors that might cause spontaneous bacterial empyema (SBEM) in patients with cirrhotic hydrothorax., Background: Pathogenic mechanism of SBEM of cirrhotic patients is probably similar to that of spontaneous bacterial peritonitis, but local factors affecting pleural fluid have not been studied., Study: Determination of C3, C4, and opsonic activity levels of pleural fluid in a cohort of patients with pleural effusions of different causes., Results: Forty-eight patients had hepatic hydrothorax; 8, heart failure and 45, exudates (9, tuberculosis; 21, malignancies; 10, other). Of the 48 cirrhotic patients, 15 developed SBEM on admission. The pleural fluid of cirrhotic patients showed significantly lower levels of total protein, complement, and opsonic activity than did the fluids of patients with other causes of SBEM. Patients who developed SBEM had lower concentrations of pleural fluid total protein and C3 and had a higher Child-Pugh score than patients who did not develop the infection., Conclusion: Cirrhotic patients with hepatic hydrothorax have lower pleural fluid opsonic activity and C3 levels than those found in the pleural fluid of patients with other causes. Patients who develop SBEM have lower levels of pleural fluid C3, pleural fluid total protein, and a higher Child-Pugh score than those who do not develop SBEM.

Published
2003
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results